GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (FRA:N4CN) » Definitions » Cyclically Adjusted FCF per Share

Paratek Pharmaceuticals (FRA:N4CN) Cyclically Adjusted FCF per Share : €-3.22 (As of Jun. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Paratek Pharmaceuticals Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Paratek Pharmaceuticals's adjusted free cash flow per share for the three months ended in Jun. 2023 was €-0.029. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-3.22 for the trailing ten years ended in Jun. 2023.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 13.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 14.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Paratek Pharmaceuticals was 49.40% per year. The lowest was 2.70% per year. And the median was 21.80% per year.

As of today (2024-06-11), Paratek Pharmaceuticals's current stock price is €2.024. Paratek Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2023 was €-3.22. Paratek Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Paratek Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Paratek Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Paratek Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.55 -5.66 -4.34 -4.32 -3.62

Paratek Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.01 -4.44 -3.62 -3.39 -3.22

Competitive Comparison of Paratek Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Paratek Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paratek Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Paratek Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Paratek Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Paratek Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-0.029/128.7287*128.7287
=-0.029

Current CPI (Jun. 2023) = 128.7287.

Paratek Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201309 -0.868 98.790 -1.131
201312 -2.539 98.326 -3.324
201403 -0.061 99.695 -0.079
201406 -0.767 100.560 -0.982
201409 -1.368 100.428 -1.754
201412 -0.784 99.070 -1.019
201503 -0.221 99.621 -0.286
201506 -0.773 100.684 -0.988
201509 -1.117 100.392 -1.432
201512 -0.826 99.792 -1.066
201603 -0.949 100.470 -1.216
201606 -1.123 101.688 -1.422
201609 -1.142 101.861 -1.443
201612 -1.021 101.863 -1.290
201703 -0.998 102.862 -1.249
201706 -0.520 103.349 -0.648
201709 -0.469 104.136 -0.580
201712 -0.675 104.011 -0.835
201803 -0.506 105.290 -0.619
201806 -0.615 106.317 -0.745
201809 -0.553 106.507 -0.668
201812 -0.519 105.998 -0.630
201903 -0.979 107.251 -1.175
201906 -0.944 108.070 -1.124
201909 -0.786 108.329 -0.934
201912 -0.951 108.420 -1.129
202003 -0.665 108.902 -0.786
202006 -0.415 108.767 -0.491
202009 -0.541 109.815 -0.634
202012 -0.428 109.897 -0.501
202103 -0.392 111.754 -0.452
202106 -0.565 114.631 -0.634
202109 0.454 115.734 0.505
202112 -0.346 117.630 -0.379
202203 -0.333 121.301 -0.353
202206 -0.259 125.017 -0.267
202209 -0.227 125.227 -0.233
202212 -0.341 125.222 -0.351
202303 0.182 127.348 0.184
202306 -0.029 128.729 -0.029

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Paratek Pharmaceuticals  (FRA:N4CN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Paratek Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Paratek Pharmaceuticals (FRA:N4CN) Business Description

Traded in Other Exchanges
N/A
Address
75 Park Plaza, 4th Floor, Boston, MA, USA, 02116
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Paratek Pharmaceuticals (FRA:N4CN) Headlines

No Headlines